This study has identified the IGF-1/IGF-IR/MEK prosurvival axis that exists in ER+ breast cancer cells to attenuate significantly the cytotoxic action of antiestrogen and antiprogestin treatment, with little effect on the antiproliferative action of these hormones. Here, ESR1 is linked to breast cancer.